Cholera Prevention: A Breakthrough in Global Vaccine Supply
The world is witnessing a significant breakthrough in the fight against cholera, a deadly disease that has plagued vulnerable communities for years. The global vaccine supply has expanded to a level that allows for the resumption of life-saving preventive campaigns, marking a crucial step towards controlling this devastating outbreak.
The announcement comes from Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO), who have been working tirelessly to address the growing cholera crisis. Mozambique is taking the lead, restarting preventive vaccination after a halt in 2022 due to a global surge in cholera cases, which led to a shortage of oral cholera vaccine (OCV) stocks.
The timing is critical. Mozambique is currently grappling with an ongoing cholera outbreak and the aftermath of floods that affected over 700,000 people and displaced many. These floods disrupted health systems and damaged water systems, exacerbating the risk of waterborne diseases like cholera.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, expressed his gratitude and urgency: "Global vaccine shortages forced us into a cycle of reacting to cholera outbreaks instead of preventing them. We are now in a stronger position to break that cycle. I thank EUBiologics, currently the only manufacturer producing cholera vaccines at the scale needed for mass vaccination campaigns, for its efforts, and urge others to enter this vital space. These vaccines will save lives."
A total of 20 million doses are being deployed for preventive campaigns. Mozambique has received 3.6 million doses, the Democratic Republic of the Congo has received 6.1 million doses to combat significant outbreaks, and Bangladesh is set to receive 10.3 million doses. These allocations were determined by the Global Task Force for Cholera Control (GTFCC), ensuring a systematic, equitable, and transparent distribution.
The global annual supply of OCV has doubled from 35 million doses in 2022 to nearly 70 million doses in 2025, thanks to the efforts of global agencies, manufacturers, and partners. Gavi finances the doses, while UNICEF procures and delivers them to countries. Dr. Sania Nishtar, CEO of Gavi, emphasized the importance of this collaboration, stating, "The multi-year surge in cholera cases and the resulting unprecedented demand for vaccines remind us that sustainable, accessible vaccine supply is a global public good."
Catherine Russell, UNICEF Executive Director, highlighted the impact of this vaccine increase: "For the first time in years, this increase in vaccines will allow us to better prevent large-scale cholera emergencies. Resuming preventive cholera vaccination will protect children and help stop this highly contagious disease. However, it must be complemented by other efforts, including improved access to safe water and basic sanitation."
Dr. Ilesh Jani, chair of the Steering Committee of the GTFCC, added, "This milestone showcases the power of collaboration among diverse partners in building a more reliable response to cholera. Preventive vaccination provides a crucial shield for communities and buys critical time. Yet, lasting progress requires long-term investment in infrastructure, which relies on political commitment."
The restoration of preventive vaccination is a result of years of sustained efforts and collaboration among agencies, manufacturers, and partners to meet the high demand for outbreak responses, expand production capacity, and streamline allocation. The OCV is safe and effective, recommended for individuals over one year old, providing short-term protection for at least six months and long-term protection for three years.
While the one-dose strategy remains the standard for outbreak responses, the use of two doses is considered on a case-by-case basis as the global vaccine supply continues to improve. Cholera remains a significant threat, spreading through contaminated food and water, causing severe diarrhea and dehydration, and leading to death if not treated promptly. It is prevalent in areas lacking safe water and sanitation, particularly in conflict-affected and impoverished regions.
The article concludes by emphasizing that vaccination is just one aspect of cholera prevention and response. Long-term investments in safe water, sanitation, hygiene infrastructure, disease surveillance, rapid treatment, and community engagement are essential to prevent outbreaks and reduce deaths in the long term. The world must remain vigilant and committed to this crucial mission.
